Molecular Diagnostics Market Size to Hit USD 38.00 Billion by 2033

Molecular Diagnostics Market Size, Share, Growth, Segmental Analysis, By Technology (Polymerase Chain Reaction — Real-Time PCR, Digital PCR, Multiplex PCR; Next-Generation Sequencing — Whole Genome Sequencing, Targeted Gene Sequencing, RNA Sequencing; In Situ Hybridization — FISH, CISH; Isothermal Nucleic Acid Amplification Technology; Microarray Technology; Others), By Product (Instruments, Reagents and Consumables, Software and Services), By Application (Infectious Disease Testing, Oncology and Cancer Diagnostics, Genetic and Rare Disease Testing, Pharmacogenomics, Blood Screening, Others), By End User (Hospitals and Clinical Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), and Market Forecast, 2026 – 2033

  • Published: Apr, 2026
  • Report ID: 434
  • Pages: 160+
  • Format: PDF / Excel.

This report contains the Latest Market Figures, Statistics, and Data.

Get a Sample
logo

Molecular Diagnostics Market Size to Hit USD 38.00 Billion by 2033

(An Updated Version is Available)

1. Preface

  • 1.1 Report Description and Scope

  • 1.2 Research Objectives

  • 1.3 Key Assumptions and Limitations

  • 1.4 Target Audience

2. Executive Summary

  • 2.1 Market Overview and Snapshot

  • 2.2 Key Market Findings and Highlights

  • 2.3 Market Size Estimation and Forecast Summary

  • 2.4 Key Trends at a Glance

  • 2.5 Recommendations for Market Participants

3. Research Methodology

  • 3.1 Research Design and Approach

  • 3.2 Primary Research (Clinical Laboratory Directors, Molecular Pathologists, Hospital Procurement Managers, KOL Interactions, IVD Industry Executives)

  • 3.3 Secondary Research (Annual Reports, FDA 510(k)/PMA/EUA Databases, EMA IVDD/IVDR 2017/746, WHO UNITAID, CDC MMWR, ClinicalTrials.gov, IQVIA Oncology Intelligence)

  • 3.4 Top-Down and Bottom-Up Estimation Approach

  • 3.5 Data Triangulation and Validation

  • 3.6 Market Forecast Assumptions and Key Parameters

4. Market Overview

  • 4.1 Introduction to Molecular Diagnostics and Their Role in Precision Disease Detection and Personalized Medicine

  • 4.2 Historical Market Background and Evolution (RFLP-Based Testing → PCR Revolution → Real-Time qPCR → NGS → Digital PCR and CRISPR-Based Diagnostics)

  • 4.3 Market Scope and Definition

  • 4.4 Parent Market and Adjacent Market Analysis (In-Vitro Diagnostics, Genomics, Companion Diagnostics, Point-of-Care Testing, Liquid Biopsy)

  • 4.5 Regulatory Overview (FDA 21 CFR Part 820/CLIA Waiver/EUA, EU IVDR 2017/746, ISO 15189, WHO Prequalification, ICH Q5E, CDSCO, NMPA, PMDA LDT Frameworks)

  • 4.6 Technology and Innovation Timeline (PCR → qRT-PCR → Multiplex PCR → NGS → Digital PCR → CRISPR-Based Diagnostics → AI-Assisted Platforms)

  • 4.7 Molecular Diagnostics vs. Immunoassays vs. Traditional Microbiology: Accuracy, Turnaround Time, and Clinical Outcome Comparison

5. Market Dynamics

  • 5.1 Market Drivers

    • 5.1.1 Rising Global Prevalence of Infectious Diseases (Tuberculosis, HIV, Hepatitis, STIs, Drug-Resistant Pathogens) Sustaining Core Molecular Diagnostics Demand

    • 5.1.2 Increasing Incidence of Cancer and Genetic Disorders Driving Oncology and Genetic Testing Applications of Molecular Diagnostics

    • 5.1.3 Growing Adoption of Point-of-Care (POC) Molecular Testing for Decentralized, Near-Patient Diagnostics (GeneXpert, ID NOW, Liat)

    • 5.1.4 Rapid Advancements in NGS, Digital PCR, Liquid Biopsy, and CRISPR-Based Diagnostic Technologies

    • 5.1.5 Surge in Government and Private Funding for Molecular Diagnostics R&D, Including NIH, BARDA, Wellcome Trust, and Global Health Security Investments

    • 5.1.6 Growing Demand for Companion Diagnostics Enabling Precision Oncology Drug-CDx Co-Launch Strategies

    • 5.1.7 COVID-19 Pandemic Legacy: Permanent Expansion of NAAT/RT-PCR Laboratory Infrastructure and Acceptance of Rapid Molecular Diagnostics

  • 5.2 Market Restraints

    • 5.2.1 High Capital Cost of Advanced Molecular Diagnostic Instruments (NGS Platforms, Digital PCR Systems) Limiting Adoption in Low-Resource Settings

    • 5.2.2 Stringent Regulatory Oversight of Laboratory-Developed Tests (LDTs) Under Proposed FDA LDT Rule Increasing Compliance Burden

    • 5.2.3 Shortage of Trained Molecular Pathologists and Laboratory Technicians in Emerging Markets

    • 5.2.4 Reimbursement Challenges for Novel NGS-Based and Liquid Biopsy Assays in Public Healthcare Systems

    • 5.2.5 Rapid Technology Obsolescence and Short Commercial Lifecycle of Molecular Diagnostic Platforms Increasing R&D Costs

  • 5.3 Market Opportunities

    • 5.3.1 CRISPR-Based Diagnostics (SHERLOCK, DETECTR) — Next-Generation Ultrafast, Low-Cost, Sequence-Specific Nucleic Acid Detection

    • 5.3.2 AI and Machine Learning Integration in Molecular Diagnostic Data Interpretation, Variant Classification, and Liquid Biopsy Signal Detection

    • 5.3.3 Expansion of Multi-Cancer Early Detection (MCED) Platforms Using ctDNA-Based Liquid Biopsy (GRAIL Galleri, Guardant SHIELD, Exact Sciences Cologuard 2.0)

    • 5.3.4 Rapid Molecular POC Expansion — Decentralized NAAT Testing in Primary Care, Emergency Departments, and Community Health Centers

    • 5.3.5 Growing Pharmacogenomics Testing Programs — PGx Panel Adoption in Hospital EHR Systems for Precision Prescribing

    • 5.3.6 Emerging Market Opportunities — India, China, Brazil, Southeast Asia Investing in National Lab Modernization and Molecular Diagnostic Capacity Building

    • 5.3.7 Digital Health Convergence — Telehealth-Linked Molecular Testing, At-Home Sample Collection (DTC kits), and Remote Result Integration

  • 5.4 Market Challenges

    • 5.4.1 Managing Post-COVID Volume Normalization — Laboratories Over-Invested in RT-PCR Capacity Now Facing Workload Rationalization

    • 5.4.2 Ensuring Analytical Validity, Clinical Utility, and Equitable Access for NGS-Based Diagnostic Applications

    • 5.4.3 Interoperability of Molecular Diagnostic Data Across LIS, EHR, and Regional Health Information Exchange Platforms

    • 5.4.4 Maintaining Cold-Chain Integrity for Molecular Diagnostic Reagents Across Tropical and Low-Infrastructure Distribution Networks

6. Market Trends and Key Insights

  • 6.1 PCR Segment Retains Dominance (62.16% Share in 2025) While Multiplex and Digital PCR Subsegments Drive Premium Growth

  • 6.2 Next-Generation Sequencing (NGS) Rapidly Expanding in Oncology, Rare Disease, and Prenatal Applications — Now Fastest-Growing Technology

  • 6.3 Liquid Biopsy Revolutionizing Cancer Monitoring — ctDNA, cfRNA, CTCs, and Exosome-Based Assays Advancing from Research to Routine Clinical Adoption

  • 6.4 CRISPR-Based Diagnostics Entering Clinical Validation — Potential to Disrupt Low-Resource Infectious Disease Testing Markets

  • 6.5 Multiplexed Syndromic Panel Testing (Respiratory, GI, Meningitis, STI Panels) Becoming Standard in Emergency and Intensive Care Settings

  • 6.6 AI-Assisted Pathology and Genomic Variant Interpretation Streamlining Molecular Laboratory Workflows and Reducing Turnaround Time

  • 6.7 Strategic M&A Reshaping Competitive Landscape — Abbott–Exact Sciences (USD 21B), Roche–Sapphiros, QIAGEN Digital Pathology Expansion

  • 6.8 WHO Prequalification and Global Health Security Investments Accelerating Molecular Diagnostic Deployment in LMICs (Tuberculosis, HIV, HPV Focus)

7. Impact Assessment

  • 7.1 Impact of COVID-19 on the Molecular Diagnostics Market

    • 7.1.1 Pre-COVID Market Scenario

    • 7.1.2 Pandemic Impact: Explosive RT-PCR Demand, Emergency EUA Clearances, Supply Chain Pressures, and NAAT Infrastructure Expansion

    • 7.1.3 Post-COVID Realignment: Volume Normalization, Portfolio Diversification, and Respiratory Syndromic Panel Market Maturation

  • 7.2 Macroeconomic Indicators and Their Influence on Market Growth

  • 7.3 Impact of FDA LDT Final Rule, EU IVDR 2017/746 Transition, WHO Prequalification Programs, and IVD Reimbursement Reforms

  • 7.4 Geopolitical Factors — U.S.-China Trade Policies (BIOSECURE Act, BGI/MGI Technologies), Supply Chain Regionalization, and Cold-Chain Infrastructure Risks

8. Strategic Framework Analysis

  • 8.1 Value Chain Analysis

    • 8.1.1 Raw Material and Biological Reagent Suppliers (Enzymes, Primers, Probes, Reference Standards, Nucleic Acid Extraction Media)

    • 8.1.2 Molecular Diagnostic Instrument Manufacturers (PCR, NGS, FISH, ISH, Digital PCR Platform Developers)

    • 8.1.3 Reagent, Kit, and Consumable Manufacturers (Assay Developers, CDx Co-Developers)

    • 8.1.4 Software and Bioinformatics Platform Providers (Variant Calling, LIS Integration, AI-Assisted Interpretation)

    • 8.1.5 Clinical and Reference Laboratory Operators

    • 8.1.6 Contract Research and Testing Organizations

    • 8.1.7 End Users — Hospitals, Clinical and Pathology Labs, Research Institutes, POC Settings

  • 8.2 Supply Chain Analysis and Risk Assessment (Reagent Shortages, Enzyme Supply Constraints, Cold-Chain Vulnerabilities)

  • 8.3 Porter's Five Forces Analysis

    • 8.3.1 Threat of New Entrants (AI-Native Diagnostics Startups, CRISPR Platform Companies)

    • 8.3.2 Bargaining Power of Buyers (Hospital Lab Networks, Group Purchasing Organizations)

    • 8.3.3 Bargaining Power of Suppliers (NGS Flow Cell Manufacturers, Enzyme and Probe Suppliers)

    • 8.3.4 Threat of Substitute Testing Methods (Immunoassays, Traditional Microbiology, Rapid Antigen Tests)

    • 8.3.5 Competitive Rivalry Among Existing Players

  • 8.4 SWOT Analysis of the Overall Market

  • 8.5 Pricing Analysis and Trends by Product, Technology, and Region

  • 8.6 Technology Landscape and Innovation Matrix

    • 8.6.1 PCR Technology — qPCR, RT-PCR, Multiplex PCR, Digital PCR, and High-Throughput PCR Systems

    • 8.6.2 Next-Generation Sequencing (NGS) — Short-Read (Illumina), Long-Read (Oxford Nanopore, PacBio), and Targeted Panel Sequencing

    • 8.6.3 In Situ Hybridization (ISH) and Fluorescence ISH (FISH) — RNAscope, Spatial Transcriptomics

    • 8.6.4 Isothermal Nucleic Acid Amplification Technology (INAAT) — LAMP, RPA, TMA, NASBA

    • 8.6.5 CRISPR-Based Diagnostics — SHERLOCK (Cas13), DETECTR (Cas12), and CARMEN Multiplex Platforms

    • 8.6.6 Liquid Biopsy and ctDNA Platforms — Cell-Free DNA/RNA, Circulating Tumor Cell (CTC) Detection

    • 8.6.7 AI and Digital Pathology Integration in Molecular Diagnostic Interpretation Workflows

  • 8.7 IP and Patent Landscape

  • 8.8 M&A Activity, Strategic Partnerships, and Funding Landscape (2022–2026)

  • 8.9 Regulatory and Standards Landscape by Region (FDA 510(k)/CLIA/LDT Rule, EU IVDR, ISO 15189, WHO Prequalification, PMDA, CDSCO, NMPA)

  • 8.10 Drivers Impact Analysis on CAGR

9. Global Molecular Diagnostics Market — By Product

  • 9.1 Overview and Market Size, 2026–2033

  • 9.2 Reagents and Consumables

    • 9.2.1 PCR Reagents (Enzymes, Primers, Probes, Master Mixes)

    • 9.2.2 NGS Library Preparation Kits and Sequencing Reagents

    • 9.2.3 ISH and FISH Probes and Reagents

    • 9.2.4 INAAT and CRISPR Diagnostic Reagents

    • 9.2.5 Others (Nucleic Acid Extraction Kits, Hybridization Buffers, Microarray Reagents)

    • 9.2.6 Market Size, Share, and Forecast (65.53% Dominant Share: High Consumable Turnover, Recurring Revenue Model)

  • 9.3 Instruments

    • 9.3.1 PCR and qPCR Instruments

    • 9.3.2 NGS Platforms (Illumina, Thermo Fisher Ion Torrent, Oxford Nanopore MinION)

    • 9.3.3 In Situ Hybridization and Microarray Scanners

    • 9.3.4 Digital PCR Systems (QIAcuityDx, Bio-Rad QX600, Thermo QuantStudio Absolute Q)

    • 9.3.5 Mass Spectrometry-Based Molecular Diagnostic Instruments

    • 9.3.6 Market Size, Share, and Forecast

  • 9.4 Software and Services

    • 9.4.1 Bioinformatics and Variant Analysis Software

    • 9.4.2 LIS/EHR Integration and Clinical Decision Support Platforms

    • 9.4.3 AI-Assisted Molecular Diagnostic Interpretation Platforms

    • 9.4.4 Market Size, Share, and Forecast (Fastest Growing Product: AI-Integration, Digital Pathology, Regulatory Compliance Tools)

10. Global Molecular Diagnostics Market — By Test Location

  • 10.1 Overview and Market Size, 2026–2033

  • 10.2 Central Laboratories

    • 10.2.1 Hospital-Based Central Molecular Laboratories

    • 10.2.2 Independent Reference and Esoteric Testing Laboratories

    • 10.2.3 Market Size, Share, and Forecast (Dominant Segment: Automation, High-Throughput Testing, Centralized Quality Management)

  • 10.3 Point of Care (POC)

    • 10.3.1 Near-Patient POC Molecular Testing (GeneXpert, ID NOW, Liat, FilmArray)

    • 10.3.2 Emergency Department and ICU POC Molecular Testing

    • 10.3.3 Market Size, Share, and Forecast (Significant CAGR: Decentralization, Pandemic Legacy, Physician Office Lab Adoption)

  • 10.4 Self-Test and OTC

    • 10.4.1 At-Home Nucleic Acid Test Kits (HPV Self-Collection, STI At-Home NAAT, DTC Sample Collection Kits)

    • 10.4.2 Market Size, Share, and Forecast (Fastest Growing Segment: Consumer Health Empowerment, Telehealth Integration)

11. Global Molecular Diagnostics Market — By Technology

  • 11.1 Overview and Market Size, 2026–2033

  • 11.2 Polymerase Chain Reaction (PCR)

    • 11.2.1 PCR by Procedure

      • 11.2.1.1 Nucleic Acid Extraction

      • 11.2.1.2 Amplification and Detection

      • 11.2.1.3 Others

    • 11.2.2 PCR by Type

      • 11.2.2.1 Multiplex PCR (Dominant Sub-Type: Syndromic Panel Testing)

      • 11.2.2.2 Real-Time qPCR

      • 11.2.2.3 Digital PCR (dPCR)

      • 11.2.2.4 Reverse Transcription PCR (RT-PCR)

      • 11.2.2.5 Other PCR Types

    • 11.2.3 PCR by Product (Instruments, Reagents, Others)

    • 11.2.4 Market Size, Share, and Forecast (62.16% Dominant Share: Widely Validated, Globally Adopted, Regulatory-Approved)

  • 11.3 In Situ Hybridization (ISH)

    • 11.3.1 Chromogenic ISH (CISH)

    • 11.3.2 Fluorescence ISH (FISH)

    • 11.3.3 RNAscope ISH (ACD/Bio-Techne)

    • 11.3.4 Market Size, Share, and Forecast (Fastest Growing Technology: RNAscope Probes for B-Cell Lymphoma, HPV, Spatial Biology)

  • 11.4 Isothermal Nucleic Acid Amplification Technology (INAAT)

    • 11.4.1 LAMP (Loop-Mediated Isothermal Amplification)

    • 11.4.2 TMA (Transcription-Mediated Amplification)

    • 11.4.3 Recombinase Polymerase Amplification (RPA)

    • 11.4.4 Market Size, Share, and Forecast

  • 11.5 Chips and Microarrays

    • 11.5.1 DNA Microarrays (Gene Expression Profiling)

    • 11.5.2 SNP Genotyping Arrays

    • 11.5.3 CGH Arrays for Copy Number Variation

    • 11.5.4 Market Size, Share, and Forecast

  • 11.6 Mass Spectrometry

    • 11.6.1 MALDI-TOF MS for Microbial ID

    • 11.6.2 LC-MS/MS for Nucleotide and Mutation Analysis

    • 11.6.3 Market Size, Share, and Forecast

  • 11.7 Transcription-Mediated Amplification (TMA)

    • 11.7.1 Market Size, Share, and Forecast

    • 11.7.2 Key Applications: STI Testing (Chlamydia, Gonorrhea, TV), Blood Screening (HIV, HCV, HBV)

  • 11.8 Next-Generation Sequencing (NGS)

    • 11.8.1 Targeted Panel Sequencing (Oncology CDx, BRCA, MSI)

    • 11.8.2 Whole-Exome Sequencing (WES)

    • 11.8.3 Whole-Genome Sequencing (WGS)

    • 11.8.4 Long-Read Sequencing (Oxford Nanopore, PacBio)

    • 11.8.5 Market Size, Share, and Forecast (Significant High CAGR: Oncology CDx, Rare Disease, Liquid Biopsy)

  • 11.9 Others (CRISPR-Based Diagnostics, Digital PCR, Pyrosequencing, Sanger Sequencing)

12. Global Molecular Diagnostics Market — By Application

  • 12.1 Overview and Market Size, 2026–2033

  • 12.2 Infectious Disease

    • 12.2.1 Sexually Transmitted Infections (STIs)

      • 12.2.1.1 Chlamydia and Gonorrhea (CT/NG NAATs — Roche Cobas, Abbott RealTime CT/NG, Hologic Aptima)

      • 12.2.1.2 HIV (HIV-1/2 Viral Load, CD4 Testing — Cobas HIV-1 VL, Abbott RealTime HIV-1)

      • 12.2.1.3 HPV (High-Risk HPV Genotyping — Roche Cobas HPV, BD Onclarity HPV, Hologic Cervista)

      • 12.2.1.4 Others (Syphilis, HSV, Trichomonas)

    • 12.2.2 Blood-Borne Infections and Blood Screening

      • 12.2.2.1 Hepatitis B Virus (HBV)

      • 12.2.2.2 Hepatitis C Virus (HCV)

      • 12.2.2.3 Blood Safety Multiplex NAATs (HIV/HCV/HBV/WNV — Grifols Procleix, Roche cobas)

    • 12.2.3 Respiratory Infections

      • 12.2.3.1 Influenza A/B (NAAT and Rapid Molecular)

      • 12.2.3.2 Respiratory Syncytial Virus (RSV)

      • 12.2.3.3 SARS-CoV-2 and Variants of Concern

      • 12.2.3.4 Multiplex Respiratory Panel (FilmArray Respiratory 2.1, BioFire RP2.1)

    • 12.2.4 Healthcare-Associated Infections (HAIs)

      • 12.2.4.1 MRSA (Methicillin-Resistant Staphylococcus aureus)

      • 12.2.4.2 Clostridium difficile (CDI PCR Assays)

      • 12.2.4.3 Vancomycin-Resistant Enterococci (VRE)

      • 12.2.4.4 Carbapenem-Resistant Bacteria

    • 12.2.5 Tuberculosis and Drug-Resistant TB (Cepheid GeneXpert Xpert MTB/RIF Ultra, Hain Lifescience GenoType)

    • 12.2.6 Meningitis and CNS Infections (FilmArray Meningitis/Encephalitis Panel, BioFire ME)

    • 12.2.7 Gastrointestinal Infections (FilmArray GI Panel, Luminex xTAG GPP)

    • 12.2.8 Others (Candida, Leishmaniasis, Dengue, Zika, Malaria Molecular Diagnostics)

    • 12.2.9 Market Size, Share, and Forecast (Dominant Application: 60.0% Share per FBI — TB, HIV, STI, HAI Burden)

  • 12.3 Oncology

    • 12.3.1 Breast Cancer (HER2 FISH, BRCA1/2 NGS, PIK3CA — Roche PATHWAY, Foundation One CDx)

    • 12.3.2 Lung Cancer (EGFR, ALK, ROS1, PD-L1, KRAS Molecular Testing — Cobas EGFR, Vysis ALK)

    • 12.3.3 Colorectal Cancer (KRAS/NRAS/BRAF MSI-H/MMR — Therascreen KRAS, Guardant360 LBx)

    • 12.3.4 Cervical Cancer and HPV (Cobas HPV, BD Onclarity HPV Assay — FDA-Approved CDx)

    • 12.3.5 Prostate Cancer (Oncotype DX Genomic Prostate Score, Decipher, PSMA Molecular Testing)

    • 12.3.6 Hematologic Malignancies (BCR-ABL qPCR, FLT3, NPM1, MRD Testing for Leukemia)

    • 12.3.7 Kidney, Liver, Ovarian, and Other Solid Tumor Molecular Profiling

    • 12.3.8 Market Size, Share, and Forecast (Fastest Growing Application: CDx Expansion, Liquid Biopsy Clinical Adoption, MCED Rollout)

  • 12.4 Genetic Testing

    • 12.4.1 Newborn Screening (NBS — Tandem MS and NGS Panel)

    • 12.4.2 Predictive and Presymptomatic Genetic Testing (BRCA, Lynch Syndrome, Hereditary CVD)

    • 12.4.3 Carrier Testing (Expanded Carrier Screening, Preconception Panels)

    • 12.4.4 Prenatal Testing (Cell-Free DNA NIPS/NIPT — Natera Panorama, GRAIL, Illumina VeriSeq)

    • 12.4.5 Pharmacogenomics Testing (PGx Panel: CYP2D6, CYP2C19, TPMT — Precision Prescribing)

    • 12.4.6 Market Size, Share, and Forecast

  • 12.5 Pharmacogenomics

    • 12.5.1 Market Size, Share, and Forecast

    • 12.5.2 Integration into Hospital EHR Systems for Routine Drug-Gene Interaction Testing

  • 12.6 Histology

    • 12.6.1 Tissue-Based Molecular Biomarker Testing (IHC, FISH, ISH for Pathology)

    • 12.6.2 Spatial Transcriptomics and Digital Pathology Integration

    • 12.6.3 Market Size, Share, and Forecast

  • 12.7 Blood Screening

    • 12.7.1 Market Size, Share, and Forecast

    • 12.7.2 Key Applications: Blood Bank Safety Testing for HIV, HCV, HBV, WNV, HTLV, Zika

  • 12.8 Neurological Diseases

    • 12.8.1 Market Size, Share, and Forecast

    • 12.8.2 Alzheimer's CSF Biomarkers, Epilepsy Genetic Panels, Neuroinflammation NAAT Assays

  • 12.9 Cardiovascular Diseases

    • 12.9.1 Market Size, Share, and Forecast

  • 12.10 Microbiology

    • 12.10.1 Market Size, Share, and Forecast

    • 12.10.2 MALDI-TOF and Molecular Microbial ID Applications in Clinical Microbiology Labs

  • 12.11 Others (Rare Genetic Disorders, Agricultural and Environmental Testing, Forensics, Food Safety Molecular Testing)

13. Global Molecular Diagnostics Market — By End User

  • 13.1 Overview and Market Size, 2026–2033

  • 13.2 Hospitals and Diagnostic Laboratories

    • 13.2.1 Hospital In-House Molecular Laboratories

    • 13.2.2 Hospital-Based Reference Molecular Labs

    • 13.2.3 Diagnostic Pathology Labs (Independent, Chain-Operated)

    • 13.2.4 Market Size, Share, and Forecast (47.5% Dominant Share per CMI: Centralized Testing, Automation, Scale Economies)

  • 13.3 Clinical and Pathology Laboratories

    • 13.3.1 Market Size, Share, and Forecast

    • 13.3.2 Specialized Reference Labs (Quest Diagnostics, LabCorp, Cerba HealthCare)

  • 13.4 Research Institutes and Academic Medical Centers

    • 13.4.1 University-Based Translational Research Laboratories

    • 13.4.2 Government Research Programs (NIH, NIHR, DBT, CNRS)

    • 13.4.3 Market Size, Share, and Forecast

  • 13.5 Others

    • 13.5.1 Physician Offices, Urgent Care Centers, and Long-Term Care Facilities

    • 13.5.2 Blood Banks and Transfusion Medicine Centers

    • 13.5.3 Public Health Laboratories (CDC, PHE, ECDC, National Reference Laboratories)

    • 13.5.4 Market Size, Share, and Forecast

14. Global Molecular Diagnostics Market — By Region

  • 14.1 Market Overview by Geography

  • 14.2 North America

    • 14.2.1 Market Size and Forecast (44.16% Dominant Share — USD 6.94 Billion in 2026)

    • 14.2.2 United States (~USD 6.62 Billion in 2026 — CDC Investment, ACS Cancer Program, FDA LDT Rule Impact)

    • 14.2.3 Canada (~247,100 New Cancer Cases in 2024 — Precision Oncology and Molecular CDx Demand)

    • 14.2.4 Mexico

    • 14.2.5 Key Drivers, Trends, and Market Dynamics

  • 14.3 Europe

    • 14.3.1 Market Size and Forecast (EU IVDR Compliance Driving Platform Upgrade Cycle)

    • 14.3.2 Germany (~USD 1.12 Billion in 2026 — Geriatric Population, GMP Molecular Platform Investments)

    • 14.3.3 United Kingdom (~USD 0.49 Billion in 2026 — NHS Community Diagnostic Centers, NIHR Integration)

    • 14.3.4 France

    • 14.3.5 Italy

    • 14.3.6 Spain

    • 14.3.7 Sweden, Norway, Denmark (Scandinavia)

    • 14.3.8 Portugal, Switzerland, Belgium, Netherlands, Turkey

    • 14.3.9 Rest of Europe

    • 14.3.10 Key Drivers, Trends, and Market Dynamics (WHO CVD Data: 42.5% European Deaths = CVD)

  • 14.4 Asia Pacific

    • 14.4.1 Market Size and Forecast (Fastest Growing Region: TB, MDR-TB Burden — 45% of Global TB in WHO SEA Region)

    • 14.4.2 China (~USD 1.12 Billion in 2026 — NMPA Platform Modernization, BGI Genomics, HGP Research)

    • 14.4.3 India (~USD 0.28 Billion in 2026 — Molbio Diagnostics, Cambrian Bioworks NGS, CDSCO Approvals)

    • 14.4.4 Japan (~USD 1.12 Billion in 2026 — PMDA Regulatory Framework, Aging Population, Oncology Platform Demand)

    • 14.4.5 South Korea (Seegene Syndromic PCR Leadership, K-BIO Initiative)

    • 14.4.6 Australia and New Zealand

    • 14.4.7 Thailand, Malaysia, Indonesia, Vietnam (PathGen Diagnostik Expansion)

    • 14.4.8 Rest of Asia Pacific

    • 14.4.9 Key Drivers, Trends, and Market Dynamics

  • 14.5 Latin America

    • 14.5.1 Market Size and Forecast (Brazil TB, Dengue, HIV Molecular Diagnostic Demand)

    • 14.5.2 Brazil

    • 14.5.3 Mexico

    • 14.5.4 Colombia, Chile, Peru, Argentina, Ecuador

    • 14.5.5 Rest of Latin America

    • 14.5.6 Key Drivers, Trends, and Market Dynamics

  • 14.6 Middle East & Africa

    • 14.6.1 Market Size and Forecast (Cancer Incidence in ME Expected to Double by 2030 per WHO)

    • 14.6.2 Saudi Arabia (USD CVD Prevalence 479,500 Projected by 2035 — Diagnostic Investment Strategy)

    • 14.6.3 United Arab Emirates

    • 14.6.4 South Africa

    • 14.6.5 Kuwait

    • 14.6.6 Rest of Middle East & Africa

    • 14.6.7 Key Drivers, Trends, and Market Dynamics

15. Competitive Landscape

  • 15.1 Market Structure and Competitiveness Overview (Moderately Concentrated — Top 5 Players Collectively Hold 34.6% Global Share; Thermo Fisher 12% Market Leader)

  • 15.2 Market Share Analysis of Key Players

  • 15.3 Competitive Positioning Matrix

  • 15.4 Key Strategies Adopted by Market Leaders

    • 15.4.1 Strategic M&A to Expand CDx and Oncology Portfolios (Abbott–Exact Sciences USD 21B, Roche–Sapphiros, Thermo Fisher–Binding Site Group)

    • 15.4.2 Platform Investment and New Product Launches (Roche USD 50B U.S. Investment, Siemens Healthineers USD 150M U.S. Manufacturing, QIAGEN QIAcuityDx Digital PCR)

    • 15.4.3 Digital Pathology and AI Integration — AI-Assisted Variant Calling, Spatial Transcriptomics, LIS/EHR Interoperability

    • 15.4.4 WHO Prequalification and Global Health Security Programs for LMICs (BD Onclarity HPV, GeneXpert MTB/RIF Ultra)

    • 15.4.5 Biosimilar and Low-Cost Molecular Diagnostic Platform Strategies for Asia Pacific, Latin America, and MEA Emerging Market Expansion

  • 15.5 Recent Developments and Industry News (2024–2026)

  • 15.6 Technology and Product Pipeline Analysis

16. Company Profiles
(The final report includes a complete list of companies)

  • 16.1 F. Hoffmann-La Roche Ltd.

    • 16.1.1 Company Overview

    • 16.1.2 Financial Performance

    • 16.1.3 Product Portfolio

    • 16.1.4 Strategic Initiatives

    • 16.1.5 SWOT Analysis

  • 16.2 Thermo Fisher Scientific Inc.

  • 16.3 QIAGEN N.V.

  • 16.4 Abbott Laboratories

  • 16.5 Danaher Corporation (Cepheid / Beckman Coulter)

  • 16.6 bioMérieux SA

  • 16.7 Becton, Dickinson and Company (BD)

  • 16.8 Hologic, Inc.

  • 16.9 Bio-Rad Laboratories, Inc.

  • 16.10 Siemens Healthineers AG

  • 16.11 Illumina, Inc.

  • 16.12 Agilent Technologies, Inc.

  • 16.13 Sysmex Corporation

  • 16.14 Seegene, Inc.

  • 16.15 Grifols, S.A.

17. Appendix

  • 17.1 Abbreviations and Acronyms

  • 17.2 List of Tables

  • 17.3 List of Figures

  • 17.4 About the Publisher

  • 17.5 Research Process and Data Sources

18. Disclaimer

Enhance your decision-making capabilities with a 5 Reports-in-1
Bundle deal for - more than 40% off!

Our professional analysts will provide you with immediate assistance.